Merck & Co., Inc. logo

Merck & Co., Inc. (6MK)

Market Closed
11 Jul, 20:00
70. 40
-1.8
-2.49%
- Market Cap
58.39 P/E Ratio
3.08% Div Yield
0 Volume
1.46 Eps
72.2
Previous Close
Day Range
70.4 71.7
Year Range
65.6 119
Want to track 6MK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 16 days

Summary

6MK closed yesterday lower at €70.4, a decrease of 2.49% from Thursday's close, completing a monthly increase of 5.07% or €3.4. Over the past 12 months, 6MK stock lost -26.97%.
6MK pays dividends to its shareholders, with the most recent payment made on Apr 07, 2025. The next estimated payment will be in 6 days ago on Jul 07, 2025 for a total of €0.81.
The last earnings report, released on Apr 24, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 29, 2025.
Merck & Co., Inc. has completed 6 stock splits, with the recent split occurring on Jun 03, 2021.
The company's stock is traded on 20 different exchanges and in various currencies, with the primary listing on NYSE (USD).

6MK Chart

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill

MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.

Zacks | 1 day ago
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals n.

Businesswire | 2 days ago
Merck (MRK) Rises Higher Than Market: Key Facts

Merck (MRK) Rises Higher Than Market: Key Facts

Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.

Zacks | 3 days ago

Merck & Co., Inc. (6MK) FAQ

What is the stock price today?

The current price is €70.40.

On which exchange is it traded?

Merck & Co., Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 6MK.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.08%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 2.04.

When is the next earnings date?

The next earnings report will release on Jul 29, 2025.

Has Merck & Co., Inc. ever had a stock split?

Merck & Co., Inc. had 6 splits and the recent split was on Jun 03, 2021.

Merck & Co., Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Robert M. Davis CEO
XMUN Exchange
US58933Y1055 ISIN
US Country
73,000 Employees
- Last Dividend
3 Jun 2021 Last Split
13 Jan 1978 IPO Date

Overview

Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.

Products and Services

The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:

  • Keytruda: A forefront immunotherapy for treating various types of cancer.
  • Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia: A portfolio of pharmaceuticals addressing hospital acute care, neuroscience, virology, cardiovascular, and diabetes.
  • Vaccine Products: Including preventive pediatric, adolescent, and adult vaccines with prominent products like Gardasil/Gardasil 9 for HPV, ProQuad, M-M-R II, and Varivax for measles, mumps, rubella, and chickenpox, RotaTeq for rotavirus, Vaxneuvance for pneumococcal infections, Pneumovax 23 for pneumonia, and Vaqta for hepatitis A.
  • Animal Health Solutions: Veterinary pharmaceuticals, vaccines, health management solutions and services, along with digitally connected identification, traceability, and monitoring products aimed at veterinarians, distributors, animal producers, farmers, and pet owners.

In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline:

  • Daiichi Sankyo's deruxtecan ADC candidates: A development and commercialization agreement covering patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for treating multiple solid tumors.
  • AstraZeneca's Lynparza and Koselugo: Co-development and co-commercialization for multiple cancer types, enhancing Merck's portfolio in oncology.
  • Collaborations across the industry: Partnerships with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well as Moderna, Inc., aiming to explore and bring new treatments and vaccines to market.

Contact Information

Address: 2000 Galloping Hill Road
Phone: 908 740 4000